TACTI-003: A randomized phase IIb study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab as first-line treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma.

被引：0

作者：

Adkins, Douglas

Cheshuk, Valerii

Peguero, Julio Antonio

Park, John J.

Lopez-Pousa, Antonio

Lybaert, Willem

Brana, Irene

Doger, Bernard

Triebel, Frederic

机构：

[1] Washington Univ, Sch Med, St Louis, MO USA

[2] ARENSIA Exploratory Med LLC, Kiev, Ukraine

[3] Oncol Consultants PA, Dept Res, Houston, TX USA

[4] Macquarie Univ, N Ryde, NSW, Australia

[5] Hosp Santa Creu & Sant Pau, Barcelona, Spain

[6] AZ Nikolaas, Dept Oncol, St Niklaas, Belgium

[7] Vall dHebron Univ Hosp, Barcelona, Spain

[8] Inst Oncol VHIO, Med Oncol Dept, Barcelona, Spain

[9] Immutep SAS, Orsay, France

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS6099

引用

页数：1